A new molecular key can unlock and disable cancer cell recycling centers
A breakthrough oral treatment for multiple myeloma uses molecular precision to block cancer cells from recycling waste, effectively starving the disease while sparing healthy tissue through advanced chemical engineering.
KYGEVVI represents a revolution in oncology by using a molecular key to disable the proteasome, the recycling center of a cancer cell. This oral solution binds to ubiquitin-tagged proteins with 100-fold selectivity, halting the degradation cycles that cancer cells rely on to survive. By utilizing stereospecific chirality, the drug evades liver metabolism to reach 90 percent bioavailability, a massive leap from the 20 percent seen in previous analogs.
There's more to this story — open the app to keep reading.